PLRX — Pliant Therapeutics Share News
0.000.00%
Last trade - 00:00- $50.52m
- -$107.59m
U.S. STOCKS ON THE MOVE-Amazon, United Parcel Service, Nike
Pliant Therapeutics up as lead drug meets main goal in liver disease trial
U.S. RESEARCH ROUNDUP-Analog Devices, Eagle Materials, Splunk
Pliant Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Pliant Therapeutics Announces Initiation Of BEACON-IPF, A Phase 2B Clinical Trial Of Bexotegrast In Idiopathic Pulmonary Fibrosis
Pliant Therapeutics Inc expected to post a loss of 71 cents a share - Earnings Preview
Pliant Therapeutics gains as Canaccord Genuity sees potential in lead drug
Pliant Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Pliant Therapeutics Inc Reports First Quarter Results
Pliant Therapeutics Inc expected to post a loss of 67 cents a share - Earnings Preview
Brief: Pliant Therapeutics Announces Positive Long-Term Data From INTEGRIS-IPF Phase 2A Trial Demonstrating Bexotegrast Was Well Tolerated At 320 Mg With Durable Improvement Shown In FVC And Across Multiple Measures
U.S. RESEARCH ROUNDUP- Apple, BlackRock, Broadcom
Brief: Pliant Therapeutics Files For Mixed Shelf Size Not Disclosed - SEC Filing
Brief: Pliant Therapeutics Announces Positive Dsmb Safety Review And Initiation Of Enrollment Of Phase 2A Trial Of Bexotegrast (PLN-74809) At 320 Mg Dose In Primary Sclerosing Cholangitis
Brief: Pliant Therapeutics Provides Corporate Update And Reports Fourth Quarter 2022 Financial Results
Brief: Pliant Therapeutics Announces Appointments Of Darren Cline And Thomas Mccourt To Board Of Directors
Brief: Pliant Therapeutics Inc Says On March 6, Co's Board Increased Authorized Size Of Board To Ten Members From Eight Members - SEC Filing
Pliant Therapeutics Inc expected to post a loss of 70 cents a share - Earnings Preview
Brief: Pliant Therapeutics Inc - On February 17, 2023, Co Received Notice From Novartis Institutes For Biomedical Research, Inc.